Application of ST3GAL6-AS1 gene, specific primer pair and kit

Abstract

The invention discloses application of an ST3GAL6-AS1 gene as well as a specific primer pair and a kit, and the specific primer pair aiming at the ST3GAL6-AS1 gene comprises an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is as shown in SEQ ID No. 1; and the nucleotide sequence of the downstream primer is as shown in SEQ ID No.2. The kit comprises a specific primer pair aiming at the ST3GAL6-AS1 gene. The ST3GAL6-AS1 gene is used as a detection marker of MM and MRD for the first time and is used for detecting multiple myeloma and multiple myeloma residues, high sensitivity and high specificity are achieved, and noninvasive detection can be achieved; and the kit disclosed by the invention not only can be applied to qualitative detection of MM and MRD, but also can be used for quantitatively determining the invasion and migration capabilities of tumor cells in the body of a patient through comparison with a reference gene.

Description

technical field [0001] The invention relates to the technical field of multiple myeloma detection, in particular to the application of the ST3GAL6-AS1 gene, a pair of specific primers and a kit. Background technique [0002] Multiple myeloma (multiple myeloma, MM) accounts for 10% of hematologic malignancies and 1% of all malignancies. MM is a malignant clonal tumor of plasma cells. Although new drugs such as lenalidomide and bortezomib have shown remarkable curative effects in recent years, it is still incurable, and all patients will eventually relapse. The main reason is that patients still have minimal residual disease (MRD) after conventional treatment, and MRD is considered to be the source of recurrence. MRD directly guides treatment and judges prognosis, so MRD needs to be monitored. At present, the commonly used MRD detection method is to collect bone marrow samples for cell morphology detection and flow cytometry immunotyping, but there are deficiencies: ① MM has...

AI Technical Summary

Problems solved by technology

At present, the commonly used MRD detection method is to collect bone marrow samples for cell morphology detection and flow cytometry immunotyping, but there are deficiencies: ① MM has unique tissue distribution characteristics, that is, the degree of infiltration and proliferation of tumor cells in the marrow is different. Focal distribution, often requires multiple punctures to detect a positive result, and the variation between multiple test results is large

② Cell morphology is highly subjective, making it difficult to differentiate benign and malignant plasma cells

And the number of myeloma cells decreased sharply after chemotherapy, even if the number of manually sorted cells exceeds the number of daily detection, it is still difficult to accurately count the number of tumor cells

③ It is difficult to unify the detection scheme and monitoring indicators of flow cytometry due to the large differences in the state of instruments and the technical level of personnel in each laboratory

However, ST3GAL6 is a non-secreted protein, which is mainly distributed in cells and can hardly be secreted into plasma, so non-invasive detection cannot be realized

[0005] In the prior art, there are few studies on the detection indicators of MM and MRD. Therefore, it is necessary to further search and study the related genes that can be used as markers in MM and MRD to realize the non-invasive detection of MM and MRD.

Images